Figure 5.

In vivo tumour protection and treatment experiments using TC-1 tumour cells with recombinant vaccinia virus. Panel A: in vivo tumour protection experiments; C57BL/6 mice (n = 10 per group) were immunised intraperitoneally twice at two weeks interval with 1 × 10⁷ pfu recombinant vaccinia virus rVVJ16/18E7E6 and rVVJ16E6E7, control virus rVVJ1175 or PBS. Two weeks after the last vaccination, mice were challenged subcutaneously in the groin with 1.2 × 10⁴ TC-1 tumour cells. Panel B: the treatment experiments; C57BL/6 mice (n = 10 per group) received 1 × 10⁴ TC-1 cells on day 0 and were vaccinated with in same groups and dose as used in panel A at days 1 and 11. Tumour development was monitored twice a week during a 50-day follow-up. The data in this figure are from one of two similar experiments.